A Comparison Between Culprit Versus Complete Revascularization in Diabetic Patients With Acute Myocardial Infarction

被引:0
|
作者
Aslanabadi, Naser [1 ]
Mashayekhi, Sina [1 ]
Rezvani, Maziar [1 ]
Abdollahzadeh, Ali [2 ]
Hajialigol, Amirhossein [3 ]
机构
[1] Tabriz Univ Med Sci, Cardiovasc Res Ctr, Dept Cardiol, Tabriz, Iran
[2] Tabriz Univ Med Sci, Sch Med, Tabriz, Iran
[3] Alborz Univ Med Sci, Alborz Off Universal Sci Educ & Res Network USERN, Karaj, Iran
关键词
acute myocardial infarction; complete revascularization; diabetes mellitus; STEMI; PERCUTANEOUS CORONARY INTERVENTION; ARTERY-DISEASE; OUTCOMES; MORTALITY;
D O I
10.1002/clc.70046
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionThe benefit of complete revascularization in diabetic patients with myocardial infarction remains unclear. this study aims to find the optimal strategy of total vascular repair for diabetic patients with acute myocardial infarction.MethodsIn an analysis of a cohort, we assigned diabetic patients with myocardial infarction who were undergoing percutaneous coronary intervention (PCI) of the culprit lesion to receive either staged complete revascularization of nonculprit lesions or to receive no further revascularization in Madani Hospital (Tabriz, Iran). Functionally significant nonculprit lesions were identified either by angiography. The primary outcome was rates of readmission, cardiac deaths, nonfatal myocardial re-infarction, and overall mortality at 1 year.ResultsIn our center, a total of 1186 patients underwent primary-PCI treatment, among which 521 were diagnosed with diabetes. Ultimately, 393 patients were selected for inclusion in the study. Within this cohort, 271 individuals (68.9%) underwent repair of only the culprit vessels (group 1), while 122 individuals (31.1%) received a comprehensive staged restoration of the vessels (group 2). During this time, group 1 in comparison with group 2 experienced 204 (75.3%) versus 97 (79.5%) cases of readmission, 48 (17.7%) versus 8 (6.5%) instances of cardiac death, 22 (8.1%) versus 18 (14.7%) occurrences of nonfatal myocardial re-infarction. Notably, the incidence of cardiac death in group 2 were significantly lower than that in group 1 (p <= 0.05).ConclusionsFor individuals diagnosed with diabetes, staged complete revascularization demonstrated a lower frequency of readmission, cardiac deaths, nonfatal myocardial reinfarction, and overall mortality, in contrast to revascularization that targeted only the culprit lesion.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Complete versus culprit only revascularization in ST-elevation myocardial infarction-a perspective on recent trials and recommendations
    Andries, Gabriela
    Khera, Sahil
    Timmermans, Robert J.
    Aronow, Wilbert S.
    JOURNAL OF THORACIC DISEASE, 2017, 9 (07) : 2159 - +
  • [42] Percutaneous Versus Surgical Revascularization for Acute Myocardial Infarction
    Enezate, Tariq
    Gifft, Kristina
    Omran, Jad
    JACC-CARDIOVASCULAR INTERVENTIONS, 2020, 13 (04) : S10 - S10
  • [43] Percutaneous Versus Surgical Revascularization for Acute Myocardial Infarction
    Enezate, Tariq
    Gifft, Kristina
    Chen, Cliff
    Omran, Jad
    Eniezat, Mohammad
    Reardon, Michael
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2021, 31 : 50 - 54
  • [44] Health-Status Outcomes in Older Patients With Myocardial Infarction: Physiology-Guided Complete Revascularization Versus Culprit-Only Strategy
    Campo, Gianluca
    Guiducci, Vincenzo
    Escaned, Javier
    Moreno, Raul
    Casella, Gianni
    Cavazza, Caterina
    Cerrato, Enrico
    Contarini, Marco
    Arena, Marco
    Iniguez Romo, Andres
    Gutierrez Ibanes, Enrique
    Scarsini, Roberto
    Vadala, Giuseppe
    Ando, Giuseppe
    Pilato, Gerlando
    Musto d'Amore, Sergio
    Capecchi, Alessandro
    Trillo Nouche, Ramiro
    Moscarella, Elisabetta
    Gambino, Alfonso
    Pavani, Marco
    Zanetti, Anna
    Pesenti, Nicola
    Dudek, Dariusz
    Barbato, Emanuele
    Tebaldi, Matteo
    Biscaglia, Simone
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2024, 17 (07): : e010490
  • [45] What are the differences between culprit and nonculprit lesions in patients with acute myocardial infarction?
    Kotani, JI
    Mintz, GS
    Castagna, MT
    Kalinczuk, L
    Pregowski, J
    Pichard, AD
    Satler, LF
    Waksman, R
    Suddath, WO
    Kent, KM
    Weissman, NJ
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 41A - 41A
  • [46] Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial
    Thiele, Holger
    Desch, Steffen
    Piek, Jan J.
    Stepinska, Janina
    Oldroyd, Keith
    Serpytis, Pranas
    Montalescot, Gilles
    Noc, Marko
    Huber, Kurt
    Fuernau, Georg
    de Waha, Suzanne
    Meyer-Saraei, Roza
    Schneider, Steffen
    Windecker, Stephan
    Savonitto, Stefano
    Briggs, Andrew
    Torremante, Patrizia
    Vrints, Christiaan
    Schuler, Gerhard
    Ceglarek, Uta
    Thiery, Joachim
    Zeymer, Uwe
    AMERICAN HEART JOURNAL, 2016, 172 : 160 - 169
  • [47] Percutaneous coronary intervention in acute myocardial infarction: treatment of the culprit vessel only versus complete revasualization
    Brosh, D.
    Assali, A.
    Ben-Dor, I.
    Teplitsky, I.
    Fuchs, S.
    Hasdai, D.
    Battler, A.
    Kornowski, R.
    EUROPEAN HEART JOURNAL, 2006, 27 : 774 - 774
  • [48] Complete versus incomplete revascularization for acute myocardial infarction with killip class III or IV subsets
    Yamane, M
    Inoue, S
    Yokozuka, H
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 330A - 330A
  • [49] Comparison of serum ferritin levels between diabetic and non-diabetic acute myocardial infarction patients
    Mahmoodi, Zohreh
    Ghaleno, Saeedeh Rashki
    TRACE ELEMENTS AND ELECTROLYTES, 2024, 41 (1-2) : 16 - 22
  • [50] COMPARISON BETWEEN ST-ELEVATION ACUTE MYOCARDIAL INFARCTION IN DIABETIC AND NON-DIABETIC PATIENTS
    Tahreem, Abeera
    Nawaz, Sobia
    Jalil, Kiran
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 5 (09): : 9440 - 9446